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Abstract
Background: Hyperhomocysteinemia (HHcy) and hyperglycemia cause diabetic cardiomyopathy by inducing
oxidative stress and attenuating peroxisome proliferator- activated receptor (PPAR) gamma. However, their
synergistic contribution is not clear.
Methods: Diabetic Akita (Ins2+/-) and hyperhomocysteinemic cystathionine beta synthase mutant (CBS+/-) were
used for M-mode echocardiography at the age of four and twenty four weeks. The cardiac rings from WT, Akita
and hybrid (Ins2+/-/CBS+/-) of Akita and CBS+/- were treated with different doses of acetylcholine (an endothelial
dependent vasodilator). High performance liquid chromatography (HPLC) was performed for determining plasma
homocysteine (Hcy) level in the above groups. Akita was treated with ciglitazone (CZ) - a PPAR gamma agonist
and tempol-an anti-oxidant, separately and their effects on cardiac remodeling were assessed.
Results: At twenty four week, Akita mice were hyperglycemic and HHcy. They have increased end diastolic
diameter (EDD). In their heart PPAR gamma, tissue inhibitor of metalloproteinase-4 (TIMP-4) and anti-oxidant
thioredoxin were attenuated whereas matrix metalloproteinase (MMP)-9, TIMP-3 and NADPH oxidase 4 (NOX4)
were induced. Interestingly, they showed synergism between HHcy and hyperglycemia for endothelial-myocyte (E-
M) uncoupling. Additionally, treatment with CZ alleviated MMP-9 activity and fibrosis, and improved EDD. On the
other hand, treatment with tempol reversed cardiac remodeling in part by restoring the expressions of TIMP-3,-4,
thioredoxin and MMP-9.
Conclusions: Endogenous homocysteine exacerbates diabetic cardiomyopathy by attenuating PPAR gamma and
inducing E-M uncoupling leading to diastolic dysfunction. PPAR gamma agonist and tempol mitigates oxidative
stress and ameliorates diastolic dysfunction in diabetes.
Background
Hyperhomocysteinemia (HHcy) is an independent cause
of cardiovascular diseases [1,2]. In diabetes, plasma
homocysteine level is elevated [3,4]. Both hyperglycemia
and HHcy lead to diabetic cardiomyopathy, which is a
leading cause of morbidity and mortality [5-9]. A posi-
tive correlation exits between plasma homocysteine
(Hcy) and left ventricular hypertrophy (LVH) in diabetes
[10]. A direct link between Hcy and cardiovascular dis-
eases is evident from the fact that every 3 μM/L increase
in Hcy level contributes to 10% increase in the risk of
coronary heart disease and 20% more chances of stroke
[11]. Hcy induces cardiac hypertrophy in rats [12,13]
and instigates bradycardia [14,15]. Hcy engenders
oxidative stress by generating reactive oxygen species
(ROS) [16,17]. In diabetes, Hcy mediated generation of
oxidative radicals induce matrix metalloproteinases
(MMPs) and inhibit their tissue inhibitors (TIMPs) that
result into extracellular matrix (ECM) remodeling
[18,19]. Additionally, activation of MMPs degrades
endothelial basement membrane [20] that connects
endothelium to myocytes through ECM and adhesion
molecules. The disruption of connection between
endothelium (E) and myocytes (M) causes E-M uncou-
pling [21,22] resulting into defective diastolic relaxation.
There are evidences suggesting the effect of Hcy on
hypertension [23], diabetes [4] and insulin resistance
[24]. However, synergism between Hcy and hyperglyce-
mia in diabetic cardiomyopathy is unclear.
The insulin2 mutant (Ins2+/-) Akita has been used as
a genetic model for type1 diabetes. Due to heterozygous
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the proinsulin2 is misfolded and cannot exocytose from
pancreatic beta cells resulting into accumulation and
ultimately death of beta cells. These mice are normogly-
cemic until the age of three week and blood glucose
level shoots up constantly after three-four weeks reach-
ing robust hyperglycemia at ten week. Akita has been
used as a model system for diabetes [25]. On the other
hand, cystathionine beta synthase mutant (CBS+/-) is
widely used as a model system for HHcy. CBS gene is
located on chromosome 17 and is required for metabo-
lism of Hcy by transsulfuration pathway [26-29]. The
double knock out of Akita and CBS+/- is not available.
To investigate individual and synergistic effect of hyper-
glycemia and HHcy, we cross-bred Akita with CBS+/-
to obtain four types of offspring: Ins2+/+/CBS+/+ (WT);
Ins2+/-, CBS+/+ (Akita); Ins2+/+/CBS+/- (CBS mutant)
and Ins2+/-/CBS+/- (double knock out).
Glucose mediated oxidative stress is mitigated by peroxi-
some proliferator- activated receptors (PPARs). They are
ligand-activated transcription factors that play pivotal role
in regulation of genes involved in hyperglycemia, lipid
metabolism, vascular tone and inflammation [30-32].
PPARg contributes in ameliorating diabetic complications
[3,33,34]. The PPARg agonists modulate insulin resistant
[33,34] and activated PPARg inhibits MMP activation [35].
Interestingly, PPARg cannot decrease plasma Hcy
[18,36-38]. Nevertheless, it is attenuated by HHcy [39]. In
a ventricular pressure overload model of mice, reduced
expression of PPARg causes left ventricular hypertrophy
[40]. The PPARg agonist (PGJ2) showed a competition for
binding to PPARg with Hcy [41] and ameliorates diabetic
cardiac hypertrophy [42]. However, the independent and
synergistic effect of Hcy and PPARg in cardiac hypertro-
phy and matrix remodeling in diabetes is nebulous.
HHcy engenders oxidative stress by inducing reactive
oxygen species (ROS) and enhances NADPH oxidase 4
(NOX4) [43]. ROS is attenuated by tempol, an anti-oxi-
dant [43,44]. The use of anti-oxidant to mitigate the effect
of oxidative stress is a promising approach for treating dia-
betic cardiomyopathy [45]. ROS also affects nitric oxide
(NO) that in contact with superoxide generates highly
reactive peroxynitrite (ONOO
-), which induces cascade of
pathological signaling. Nitric oxide (NO) is a vasodilator
and is considered as cardioprotective molecule that main-
tains E-M coupling. This study was designed to investigate
association between Hcy and glucose in structural and
functional remodeling of endocardium by defining their
link to PPARg and NO metabolism in diabetes. We
hypothesize that E-M uncoupling in diabetes is due in part
to increased level of homocysteine causing activation of
latent MMP-9, attenuation of thioredoxin and TIMP-4 in
response to antagonizing PPARg.
Methods
Animal model
Akita, CBS+/- and C57 BL/6J (WT) were procured
from Jackson Laboratory (Bar Harbor, ME). To avoid
gender specific complexity, only male mice were used
for the experiments. They were housed in the animal
care facility of University of Louisville and fed stan-
dard mouse chow diet. The animal room was main-
tained at 22-24°C with 12:12 hour light-dark cycle. At
the end of experiments, animals were sacrificed fol-
lowing the protocol approved by Institutional Animal
Care and Use Committee of University of Louisville.
Further, animal care and use programs were carried
out according to standard protocol and guidelines of
National Institute of Health (NIH) and Guide for the
Care and Use of Laboratory Animals (NIH Pub. No.
86-23, revised 1985) and regulation of Animal Welfare
Act.
Genotyping of Akita and CBS mutant mice
DNA was extracted from the tail tip of mice at the age of
six to eight weeks and was amplified by PCR using speci-
fic primer sequences. The primer sequence for Ins2 gene
was designed from the region of exon 3 because Ins2
mutation in Akita disrupts Fnu 4 HI site in the exon 3 of
Ins2 and digestion with Fnu 4 HI did not change the size
of PCR product from mutated allele (280bp), rather it
decreased the size of the wild type allele to 140 bp. The
primer sequences were forward: 5’TGC TGAT GCC
CTG GCC TGCT 3’; reverse: 5’ CAC ATA TGC ACA
TG 3’. For CBS heterozygous mutation, primer sequences
were designed from intron 3 flanking the region of neo
insert in CBS gene [46]. The primer sequences were for-
ward: 5’ GCCTCTGTCTGCTAACCTA3’;r e v e r s e :5 ’
GAGGTCGACGG TATCGATA3’.T h eP C Rp r o d u c to f
CBS from wild type is 800 bp, while the disrupted/
mutant allele was 180 bp.
Double knock out and treatment groups
To obtain the double knock out of Akita and CBS+/- (Ins2
+/-/CBS+/-), female Akita were crossed with male CBS+/-
(2♀:1 ♂). Four types of offspring were produced: WT,
Akita, CBS+/- and double knock out (Ins2+/-/CBS+/-). At
the age of twenty week, these offspring were treated with
vehicle (normal drinking water), PPARg agonist ciglitazone
(CZ-Cal Biochem Corp, CA, USA) -8 μg/ml and anti-oxi-
dant tempol (Sigma Aldrich, USA)-10 mM/L for four
weeks through drinking water. Both CZ and PPARg bind
at the micromolar range [31]. Assuming the total blood
volume 2 ml and daily drinking water intake 5 ml, the 8
μg/ml of CZ in drinking water added into the blood ~ 2
mg CZ/kg body weight/day producing a blood concentra-
tion of ~32 μM/L, which was enough to saturate the
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of PPARg agonist [48], food and water intake was mea-
sured every second day during the treatment. Additionally,
liver was weighed at the end of experiments (data not
shown) to confirm that there was no peroxisome prolifera-
tion and hepatotoxicity [49] after treatment with CZ as
reported with other PPARg-agonists [50].
Blood glucose measurement
A glucometer with one-touch strip was used to measure
the blood glucose level in mg/dL.
HPLC for Hcy level measurement
Blood drawn from the dorsal aorta of mice with the help
of heparin rinsed syringe was collected in an Eppendorf
tube on ice. It was immediately centrifuged at the rate
of 5000 rpm for 10 min at 4°C. The clear plasma was
collected and stored at -80°C and used for HPLC. Hcy
in the plasma samples was detected using a Shimadzu
Class-VP 5.0 chromatograph (Shimadzu) as described
previously [51].
Echocardiography
M-mode echocardiogram was obtained from a SONO-
5500 echocardiographic system equipped with a 12
-MHz phased- array transducer. The transducer was
placed on the left hemithorax of mice so that echocar-
diogram could be taken from a short-axis view of the
left ventricle at or just below the tip of the mitral-valve
leaflet. Only those echocardiograms, which showed well-
defined continuous interfaces of the septum and poster-
ior wall, were collected and ventricle volume and axis
lengths were determined.
Cardiac ring preparation and study of relaxation response
Transverse sections of approximately 2-3 mm thickness
that appeared as “doughnut” was prepared from left
ventricle (LV) after removing the right ventricle. The
heart was sectioned transmurally in such a manner that
LV rings (cardiac ring) of even thickness could be
obtained. The rings were immediately mounted on a
polygraph in a tissue myobath containing physiological
saline solution (PSS-118 mM NaCl, 4.7 mM KCl, 2.5
mM CaCl2, 1.2 KH2PO4, 1.2 MgSO4, and 11.2 Dextrose)
maintained at 37°C. After stretching the ring, it was
brought to the resting tension where 20 mM CaCl2 was
applied. When the contraction was maximum, different
doses of acetylcholine was added to myobath. Acetyl-
choline stimulates endothelial dependent contraction.
To avoid the orientation dependent variation in contrac-
tion measurement, two measurements at the rotation of
cardiac rings at 90° was determined and average was
used. The maximum contraction by 20 mM CaCl2 was
taken as 100% contraction and percentage relaxation
was calculated as a fraction of 100% contraction.
Further, to avoid ischemia, the myobath was bubbled
with a mixture of 95% oxygen and 5% carbon dioxide
throughout the experiment and the experiment was
completed within 40 min [52].
RT-PCR
The reverse-transcription polymerase chain reaction was
performed after extracting RNA from left ventricle. The
Promega RT-kit was used for reverse transcription fol-
lowing the method as described elsewhere [53]. The
mRNA levels of PPARg,N O X 4 ,T r x ,M M P - 2 ,- 9a n d
GAPDH were determined by RT-PCR using following
primers: Thioredoxin (Trx) sense: 5’ TGGATC-
CATTTCCATCTGGT 3’ antisense: 5’ CCTTGTTAG-
CACCGGAGAAC 3’,G A P D Hs e n s e :5 ’ TGAAGGTCG
GTGTG AAC GGATTTGGC 3’ antisense: 5’ CATG-
TAGGCCATGAGGTCCACCAC3’, MMP-2 sense: 5’
GCACTCTGGAGCGAGGATAC 3’ antisense: 5’GCCC
TCCTAAGCCAGTCTCT3’,M M P- 9s e n s e :5 ’ AAGG-
CAAACCCTGTGTGTTC3’ antisense: 5’GTGGTTC
AGTT GTGGTGGTG3’,N O X 4s e n s e :5 ’ CCA GAA
TGA GGA TCC CAG AA 3’ antisense: 5’ TGG AAC
TTG GGT TCT TCC AG3’, PPARg sense: 5’ ATGGC-
CATTGAGTGCCGAGTCTG3’ antisense: 5’GGCTTTT
GAGGAACTCCCTGGT CA3’.T h eP C Rp r o g r a mf o r
MMP-2,-9 and GAPDH was 94°C-2 min, [94°C -30 sec,
57°C -30 sec, 72°C -1 min] x30, 72°C-2 min. For Trx
and Nox4, the PCR programs were 94°C-5 min, [94°C-
40 sec, 55°C-40 sec, 72°C-1 min] × 30, 72°C-5 min and
94°C-2 min, [94°C-1 min, 53°C- 1 min, 72°C-1 min] ×
30, 72°C -5 min, respectively.
Protein extraction and Western Blotting
The left ventricle from freshly extracted heart was
homogenized in Ripa buffer (Boston BioProducts, Wor-
cester, MA, USA) with proteinase inhibitor cocktail
(Sigma, Saint Louis, MO, USA) and centrifuged at 5000
rpm for 5 min at 4°C. The supernatant was collected.
The concentration of proteins was estimated by Brad-
ford method as described elsewhere [53]. The Western
blotting was performed by following the same protocol
as described earlier [53].
Statistical analyses
A tl e a s tf i v em i c ew e r eu s e df r o me a c hg r o u pa n dd a t a
were presented as mean and standard deviation (SD).
Student t-test was used and a value of p < 0.05 was con-
sidered as significant.
Results
The comparison of blood glucose level of Akita and WT
at four and twenty four weeks revealed that at four
week both WT and Akita are normoglycemic. However,
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at twenty four week in Akita (Figure 1A). To investigate
the effect of hyperglycemia on Hcy, plasma Hcy level
was determined in the same groups of animals. Concur-
rent with the glucose level, there was significant eleva-
tion in Hcy level in twenty four week Akita (Figure 1B).
To determine whether elevation of glucose and Hcy
level had effect on the cardiac function, M-mode echo-
cardiography was performed, which showed increase in
end diastolic diameter (EDD) in twenty four week Akita
(Figure 1C). Since both glucose and Hcy level was
enhanced in Akita (Figure 1A, B), the independent and/
or synergistic effect of Hcy and glucose on cardiac dys-
function was determined by using double knock out
(Ins2+/-/CBS+/-). The genotypes of the mutants were
confirmed by PCR using Ins2 and CBS specific primers
(Figure 2). The double bands represent heterozygous
mutation (Figure 2). The plasma Hcy level was deter-
mined in the mutants and compared with WT. Hcy
level was significantly high in both CBS+/- and Ins2+/-
when compared with WT (Figure 3). Interestingly, in
double knock out, Hcy level increased almost two-fold
as compared to that of Akita. Notably, the elevation of
Hcy level was significantly (p < 0.05) higher in double
knock out when compared to CBS+/- (Figure 3). The
expression of PPARg, NOX-4 and Trx was measured in
a l lf o u rg r o u p s( W T ,I n s 2 + / - ,C B S + / -a n dC B S + / - / I n s 2
+/-). It revealed a significant increase in NOX-4, while
decrease in PPARg and Trx in all the three mutants
(CBS+/-, Ins2+/- and Ins2+/-/CBS+/-) (Figure 4).
Figure 1 A: Measurement and comparison of blood glucose level: Blood glucose level was determined at four and twenty four weeks
in WT and Ins2+/- that showed robust hyperglycemia at twenty four week Akita. B: Determination and comparison of plasma
homocysteine (Hcy) level: Plasma Hcy level was determined by high performance liquid chromatography (HPLC) at four and twenty four weeks
in male WT and Ins2+/-. There was significant elevation in Hcy level at twenty four week in Akita. C: Echocardiogram and end diastolic diameter
(EDD): Echocardiography was performed at four and twenty four weeks in male WT and Ins2+/- using SONO 5500 device. The diastolic diameter
is shown by double headed arrow. It was increased at twenty four week in Akita. The end diastolic diameter (EDD) was significantly increased at
twenty four week in Akita. Each bar represents average +SD of ten animals. *, p < 0.05 compared to WT.
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and down regulation of MMP-2 in CBS+/- (Figure 4).
Remarkably, the total urinary protein concentration was
increased in the above three mutants (Figure 5). To
determine the E-M uncoupling, cardiac rings from the
four groups were treated with different doses of acetyl-
choline after pre-constriction by CaCl2 and their rate of
relaxation was measured (Figure 6A). There was a clear
gradient decrease in the rate of relaxation in WT, CBS
+/-, Ins2+/- and Ins2+/-/CBS+/- (Figure 6B).
To determine the role of PPARg in diabetic cardio-
myopathy, Akita was treated with CZ. The activity of
MMP-9 was determined in WT and Akita with and
without treatment with CZ. There was up regulation of
MMP-9 activity in Akita. However, it was attenuated
after treatment with CZ (Figure 7). The collagen deposi-
tion, which indicates fibrosis, was also decreased in
Akita after treatment with CZ (Figure 8). The diastolic
function is reflected through diastolic diameter. It was
improved in CZ treated Akita (Figure 9). To determine
the effect of oxidative stress on diabetic cardiomyopathy,
Akita was treated with tempol, an anti-oxidant. The
results showed mitigation of NOX-4 and enhancement
of Trx level in tempol treated Akita (Figure 10). Addi-
tionally, MMP-9 and TIMP-3 were attenuated, while
MMP-2 and TIMP-4 were induced in tempol treated
Akita (Figure 10). Nevertheless, there was no change in
the TIMP-1 expression (Figure 10).
Discussion
There are two insulin genes in mice: insulin 1 and insu-
lin 2. Insulin 2 is predominantly involved in glucose
metabolism and is homologous to human insulin.
Recent clinical data revealed that mutation in insulin 2
is a major cause of neonatal diabetes [54]. Therefore,
insulin 2 mutant Akita mouse that resembles human
hypoinsulinemia has been used for investigating the
mechanism of diabetic cardiomyopathy. Hypoinsuline-
mia in later stage leads to insulin insensitivity- a feature
of type 2 diabetes [55]. The four groups obtained by
cross- breeding Ins2+/- with CBS+/- provides insight
into the independent and synergistic implications of
HHcy and hyperglycemia on diabetic cardiomyopathy.
The proinsulin maturation and exportation to cytoplasm
Figure 2 Genotyping of Ins2+/-, CBS +/- and Ins2+/-/CBS+/-.
Two PCR products suggest the heterozygous mutation, while single
band represents WT allele. In Ins2+/- and CBS +/-, the double bands
of specific PCR product confirmed the heterozygous mutation of
Ins2 and CBS genes, respectively.
Figure 3 Determination and comparison of plasma Hcy level by HPLC: The peak of plasma Hcy was shown in WT and Ins2+/-.H c y
level was determined and compared among WT, Ins2+/-, CBS +/- and Ins2+/-/CBS+/-. Each bar represents average +SD from six animals.
*, p < 0.05 compared to WT; ** p < 0.05 compared to Ins2+/-, and ***, p < 0.05 compared to CBS+/-.
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weeks. Therefore, glucose and Hcy level was determined
and compared between WT and Akita at four week. We
did not find any significant change in glucose and Hcy
level and end diastolic diameter (EDD) at four week in
Akita. However, there was robust hyperglycemia and
HHcy accompanied by increase in EDD at twenty four
week (Figure 1A, B, C). The increase in EDD at twenty
four week (Figure 1C) suggests diastolic dysfunction.
These results support previous findings of diabetic car-
diomyopathy in Akita [24,25,54,55].
Hybrids of Ins2+/- and CBS+/- were confirmed by
g e n o t y p i n g( F i g u r e2 ) .T h et w o - f o l di n c r e a s ei ng l u c o s e
and Hcy level in Ins2+/-/CBS+/- suggests synergism in
HHcy and hyperglycemia. This finding tempted us to
Figure 4 Expression of PPARg, oxidative radicals and MMPs: RT-PCR of NOX -4, PPARg, thioredoxin (Trx) and MMP-2,-9 from the heart
tissue of Ins2+/-, CBS +/- and Ins2+/-/CBS+/-. GAPDH was used as a loading control. The bar graph is made from the scanned arbitrary unit
showing mean and standard deviation of eight animals. *, p < 0.05.
Figure 5 The protein content in urine was estimated on daily
basis for 7 days and mean urinary proteins is shown with
standard deviation for WT, Ins2+/-, CBS+/- and Ins2+/-/CBS+/-.
n = 5; *, p < 0.05 compared to WT; #, p < 05 compared to CBS+/-.
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metabolism and inducing hyperhomocysteinemia in CBS
+/- (Figure 3). However, further investigations are
required to dissect the detailed mechanism. Oxidative
stress generated by HHcy [53] is mitigated by PPARg.
The analyses of results (Figure 4) revealed increase in
oxidative stress in Ins2+/-, CBS+/- and Ins2+/-/CBS+/-
as compared to WT due in part to attenuation of
PPARg [41,42]. The increase in oxidative stress in HHcy
and diabetic mice extend support to the other published
reports [16-18,43]. The down regulation of PPARg in
diabetic mice is consistent with the previous finding
[21].
Increase in oxidative radicals activates latent MMPs. It
is found that MMP-2 and MMP-9 play important role
in cardiac remodeling [56-59]. Therefore, we determined
the individual and combined effect of hyperglycemia
and HHcy on MMP-2 and MMP-9. The results revealed
induction of MMP-9 both in Akita and CBS+/-. Inter-
estingly, there was synergism between hyperglycemia
and HHcy for MMP-9 induction (Figure 4). MMP-2 was
attenuated both in Akita and CBS+/- but remained
unchanged in Ins2+/-/CBS+/- (Figure 4). It indicates
that the active site for inducing MMP-2 for either Akita
or CBS+/- was antagonized or inhibited in Ins2+/-/CBS
+/-. The induction of MMP-9 in HHcy (CBS+/-) and
Figure 6 Effect of acetylcholine (ACH) on contraction of cardiac muscle. Calcium chloride was applied on the cardiac ring (uniform
transverse section of the LV) for maximum pre-contraction followed by dose dependant treatment of ACH. A. The upper and lower panels
represent the contraction pattern of WT and Ins2+/-/CBS+/-, respectively. B. The percentage relaxation (indicating the potential of contraction)
was calculated with respect to the maximum contraction after treatment with 20 mM CaCl2 and compared among WT, CBS+/-, Ins2+/- and Ins2
+/-/CBS+/-. The capability of contraction decreased in the increasing order of CBS +/-, Ins2+/- and Ins2+/-/CBS+/- when compared to WT. Each
data point represents mean ± SD of at least six animals.
Figure 7 In - gel gelatin Zymography to determine the activity
of MMP-9 in WT, Ins2+/-and Ins2+/- treated with ciglitazone.
Beta-actin was used as a loading control. The collagen substrate
chelating represents the activity of MMP-9 and indicated by white
bands. It was higher in Akita (two bands in the middle) as
compared to WT. The treatment with ciglitazone reduced the
activity of MMP-9 in Akita.
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The blue stain represents collagen deposition. Collagen deposition was increased in Ins2+/- and attenuated after treatment with ciglitazone.
Figure 9 Diastolic diameter of Ins2+/- with and without treatment with ciglitazone. The echocardiogram shows amelioration of diastolic
diameter (double headed arrow) of Ins2+/- after treatment with ciglitazone.
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with the earlier findings [17,20,53,56].
Chronic diabetes ultimately leads to multi-organ fail-
ure. The alteration in the amount of urinary protein
indicates the internal damage of the body [60]. The total
urinary protein of twenty four week Akita, CBS+/- and
Ins2+/-/CBS+/- was compared with WT (Figure 5). We
found an increased level of total urinary protein in both
Akita and CBS+/-. Interestingly, the total urinary protein
was almost two fold increased in Ins2+/-/CBS+/-
suggesting synergistic effect of hyperglycemia and HHcy
(Figure 5).
Extracellular matrix bridges endothelium and myocyte,
which is essential for maintaining the E-M coupling.
The E-M coupling is required for the synchronized beat-
ing of cardiomyocytes, and proper systolic contraction
and diastolic relaxation of the heart. Defective E-M cou-
pling leads to heart failure. For proper contraction of
cardiomyocytes, calcium ion is indispensable. The car-
diac rings from the four groups were exposed to 20 mM
Figure 10 Effect of tempol (anti-oxidant) on Ins2+/-: Western blots showing expression of NOX-4, thioredoxin (Trx), MMP-2,-9 and
TIMP-1,-3,-4 in the heart tissue of WT, Ins2+/- and Ins2+/- treated with tempol (Akita/Tempol). (i) The expression of NOX-4 increased and
Trx decreased in Akita as compared to WT. However, it was attenuated after treatment with tempol. The expression of MMP-9 and TIMP-3 was
increased, while MMP-2 and TIMP-4 was decreased in Akita. The treatment with tempol ameliorated the expression of MMP-2,-9 and TIMP-3,-4.
There was no change in the expression of TIMP-1. Beta-actin was used as a loading control. (ii) Bar graph was based on the scanned arbitrary
unit of the bands and represents the mean ± SD of six animals. *, p < 0.05 to WT; #, p < 0.05 to Akita.
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representative graph (Figure 6A). After maximum con-
traction, cardiac rings were exposed to increasing doses
of acetylcholine that allows endothelial dependent con-
traction. The percentage relaxation was recorded from
the maximum contraction (Figure 6B). The higher per-
centage relaxation suggests healthy heart as shown by
WT (Figure 6B). We found decrease in the percentage
relaxation in CBS+/- and Akita (Figure 6B). In Ins2
+/-/CBS+/-, there was almost no capacity for relaxation
suggesting deterioration of E-M coupling (Figure 6B).
These findings reinforce synergism between hyperglyce-
mia and HHcy for E-M uncoupling in Akita. It supports
the previous finding that E-M uncoupling is one of the
major causes of diabetic cardiomyopathy [21].
To confirm the role of PPARg in diabetic cardiomyo-
pathy, Akita was treated with CZ- a PPARg agonist.
Since MMP-9 is elevated in Akita (Figure 4) and it
causes fibrosis [58], the activity of MMP-9 and level of
fibrosis was determined in Akita after treatment with
CZ and compared with WT. In twenty four week Akita,
t h ea c t i v i t yo fM M P - 9( F i g u r e7 )a n df i b r o s i s( F i g u r e8 )
was induced. However, Akita treated with CZ showed
reduced MMP-9 activity and less fibrosis as compared
to the untreated group (Figure 7, 8). As PPARg inhibits
the oxidative radicals, it was assumed that the activity of
MMP-9 would be inhibited and thereby fibrosis would
be ameliorated. The therapeutic effect of CZ was also
confirmed by echocardiography, where EDD was
decreased in CZ treated Akita (Figure 9). These findings
suggest that PPARg mitigates the effect of MMP-9 and
has cardio-protective role in diabetes. It is consistent
with the finding that activation of PPARg improves
endothelial function and thereby mitigates the diabetic
cardiomyopathy [30]. Further, PPARg is also implicated
in the modulation of metabolic syndrome that causes
cardiovascular complications [30]. The critical role of
PPARg in diabetes and cardiovascular diseases suggest
that it can be used as a therapeutic target for diabetic
cardiomyopathy.
To investigate the generation of oxidative radicals, the
levels of oxidant (NOX-4) and anti-oxidant (Trx) was
determined in WT and Akita. The up regulation of
NOX-4 and down regulation of Trx suggests oxidative
stress in Akita (Figure 10). TIMP-1 is associated with
fibrosis [58,61,62], while TIMP-3 [58,63] is associated
with apoptosis. Contrary to our expectation, there was
no significant change in the expression of TIMP-1 (Fig-
ure 10) suggesting that anti-oxidant tempol does not
have direct effect on TIMP-1. However, TIMP-3 was
inhibited by tempol (Figure 10) indicating that tempol
mitigates apoptosis by inhibiting oxidative radicals.
TIMP-4 is abundant in the heart and has cardio-protec-
tive role [58]. Tempol treated Akita had attenuated
Figure 11 A model for diabetic cardiomyopathy. In diabetes, elevated level of homocysteine induces oxidative radicals by antagonizing
PPARg that activates matrix metalloproteinases (MMPs), which in turn causes fibrosis and endothelial-myocytes disconnection. It results into
endothelial-myocytes uncoupling that ultimately leads to diastolic dysfunction. PPARg agonist and anti-oxidants mitigate the effect of oxidative
radicals, inhibit the activity of MMPs and thereby ameliorate diastolic dysfunction.
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of oxidative stress in Akita. The mitigation of cardio-
myopathy by tempol is reinforced by attenuation of
MMP-9, TIMP-3 and induction of TIMP-4 (Figure 10).
It suggests that MMP-9 and TIMP-3, -4 are largely
involved in diabetic cardiomyopathy in Akita. These
findings support the anti-oxidant effect of tempol [43].
The clinical trails failed to provide any beneficial effect
of anti-oxidant treatment (specifically vitamin C and E)
for cardiovascular therapy in Heart Outcomes Preven-
tion Evaluation (HOPE), Study to Evaluate Carotid
Ultrasound changes in patients treated with Ramipril
and vitamin E (SECURE), and Secondary Prevention
with Antioxidant of Cardiovascular disease in End stage
renal disease (SPACE) [45]. Nonetheless, these trails suf-
fer from several limitations. One of the limitations was
that these trials were not designed specifically for asses-
sing the impact of anti-oxidant on diabetes patients.
Notably, in specific trial for oxidative stress, where
patients on hemodialysis were exposed to high oxidative
stress and supplemented with vitamin E showed remark-
able response [64] suggesting that anti-oxidant could
ameliorate the pathological condition. Although,
plethora of evidences supports the anti-oxidant effect of
tempol [65-68], hitherto no clinical data is available for
its effect on diabetic cardiomyopathy. Our findings
extend support to the fact that PPARg and tempol are
promising therapeutic targets for diabetic
cardiomyopathy.
Based on our findings, we conclude that in diabetes,
HHcy antagonizes PPARg and induces production of
oxygen radicals that enhances MMP-9 and inhibits
TIMP-4, which in turn causes matrix remodeling, E-M
uncoupling and fibrosis impairing diastolic functions.
There is synergism between HHcy and hyperglycemia in
diabetic cardiomyopathy. The treatment with PPARg
agonist (CZ) and anti-oxidant (tempol) mitigates oxida-
tive stress and thereby ameliorates diastolic dysfunction
in diabetes (Figure 11).
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